James Condulis, an analyst from Stifel Nicolaus, maintained the Buy rating on Cytokinetics. The associated price target was raised to $96.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
James Condulis has given his Buy rating due to a combination of factors that highlight Cytokinetics’ promising future. The recent developments at the European Society of Cardiology (ESC) have been particularly favorable for Cytokinetics, especially regarding their drug aficamten. This drug has shown a strong potential in treating obstructive hypertrophic cardiomyopathy (oHCM) with a best-in-disease profile, and it also presents credible opportunities in non-obstructive hypertrophic cardiomyopathy (nHCM).
Furthermore, the upcoming launch of aficamten in the oHCM market is expected to benefit from Bristol-Myers Squibb’s extensive market infrastructure, enhancing its market position. The anticipated success of the ACACIA-HCM trial in the first half of 2026, along with additional pipeline opportunities such as heart failure with preserved ejection fraction (HFpEF), adds to the stock’s appeal. Condulis also increased the probability of success for Cytokinetics’ projects, reflecting confidence in their clinical trials and market potential, which collectively support the Buy rating.
In another report released today, Citi also maintained a Buy rating on the stock with a $84.00 price target.